Primary Pulmonary Liposarcoma with Pancreatic Metastasis: A Rarest of Rare Intrathoracic Malignancy

Abstract
Liposarcoma of the lung is an extremely rare malignancy with <20 cases reported so far. With such limited evidence, natural history and appropriate management of this unusual tumor is unclear. We experienced a case of primary pulmonary myxoid liposarcoma in a 34-year-old male who presented with multiple distant site metastases including pancreas, which is again an extremely rare finding accounting for approximately 2% of pancreatic malignancies. Indexed case was treated with systemic chemotherapy.

Keywords: Lung primary, myxoid liposarcoma, pancreatic metastasis

Introduction
Primary pulmonary liposarcoma is an extremely rare malignancy with <20 cases reported in literature.[1,2] Intrathoracic liposarcomas are uncommon, and if at all encountered, are usually located in the mediastinum.[3] Malignant degeneration of a pulmonary lipoma and pleuropulmonary asbestosis have been considered as possible pathogenetic factors.[4] We herein present a widely metastatic case of primary pulmonary liposarcoma in a 34-year-old man who was treated with palliative chemotherapy.

Case Report
An otherwise well, 34-year-old male with no history of tobacco addiction presented with hemoptysis, intermittent fever, and significant weight loss for 1 year. Examination revealed a 5 cm × 4 cm right axillary lymph node and decreased breath sounds over the left upper lung region, apart from which no other abnormality was detected. Contrast-enhanced computed tomography (CT) of the thorax showed a large neoplasm adjacent to bifurcation of the left main bronchus causing complete collapse of the left lung [Figure 1]. CT-guided biopsy from the lung mass was done for histopathological examination (HPE), which showed features of high-grade myxoid liposarcoma [Figure 2a and b]. Tumor cells were positive for S100 and Ki 67 was 15%. [18]F-fluorodeoxyglucose (FDG) positron emission tomography (PET)-CT scan revealed a mild hypermetabolic predominantly hypodense cystic lesion seen involving the left lung upper lobe inferiorly extending up to the left hilar region, causing abrupt cut-off of main bronchus and encasing upper and lower lobe bronchi causing distal complete collapse consolidation of the left lung upper and lower lobes [Figure 3a]. Mildly FDG-avid metastatic sites included bilateral axillary lymph nodes, right latissimus dorsi muscle, and hypodense cystic lesion involving pancreas [Figure 3b and c]. In lieu of widely metastatic disease, he was started on palliative chemotherapy with MAID regimen consisting of MESNA, Adriamycin, ifosfamide, and dacarbazine chemotherapeutic agents.

Discussion
Liposarcoma is the most common mesenchymal tumor in adults.[5] Most frequent occurrence is seen in the retroperitoneal space or in the lower extremities. The primary thoracic liposarcoma is unusual. If reported, it usually arises from mediastinum.[5] Exhaustive literature search suggests that fewer than twenty cases have so far been reported.[1,2] It shows...
Halder, et al.: Primary pulmonary liposarcoma with pancreatic metastasis

606

Indian Journal of Medical and Paediatric Oncology | Volume 41 | Issue 4 | July-August 2020

and signs attributable to sarcoma of the lung, similarly as is seen in our case. Liposarcoma is subclassified histologically into well-differentiated, myxoid, round-cell, pleomorphic, dedifferentiated, and mixed types.[5] After careful HPE of the index liposarcoma case, we considered that the cell differentiation, the mitotic index, presence of necrosis, and the proliferative activity of the tumor cells, defined the lesion as high-grade myxoid liposarcoma. Myxoid liposarcoma typically presents as a slow-growing, large mass and remains asymptomatic for several years; although there is a risk of recurrence, chance of metastases seems rare.[5,7] On the contrary, our index case presented with upfront widespread metastases including pancreas which is anyhow an extremely rare finding accounting for approximately 2% of pancreatic malignancies, hence featuring our presented case immensely unique.[8] However, metastases to the lung, pleura, liver, bone, kidneys, adrenal glands, and mediastinal lymph nodes have been reported for this category of tumor.[7] This tumor presents difficult diagnostic dilemmas pertaining to pathology and CT appearances.[5] Distinction of pulmonary liposarcoma from mediastinal variant requires careful radiographic evaluation, surgical evaluation, or both. Although definite conclusion regarding its appropriate management is difficult to draw from these limited evidences, based on information from all previously published reports, it appears that patients with primary pulmonary liposarcoma may benefit most from adequate surgical excision combined with radiation therapy.[6] Adjuvant irradiation at a dose level of 60–66 Gy after wide local excision has been shown to improve the local control rate and probably the overall survival in lot of patients.[9] Tumor recurrence is common in cases where complete surgical excision with clear margins was not possible. Chemotherapy has been used in both adjuvant and palliative settings, with highest activity observed with ifosfamide, anthracyclines, and dacarbazine based chemotherapy.[10]

Conclusion

The primary pulmonary liposarcoma is an extremely rare tumor with potential of local complications and distant metastases. The outcome depends on the precise pathologic diagnosis, stage at diagnosis, the adequacy of surgical intervention, and the use of adjuvant therapy in the form of radiotherapy and/or chemotherapy. Systemic chemotherapy has to be employed in metastatic settings.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

References